Arcturus Therapeutics (ARCT) Tops Q3 EPS by 31c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.26), $0.31 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $41.67 million versus the consensus estimate of $53.46 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi
• Tenable Holdings, Inc. (TENB) call put ratio 80 calls to 1 put with a focus on 200 contracts of July 32 calls as share price up 5.6%